The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.10
Bid: 0.05
Ask: 0.15
Change: -0.025 (-20.00%)
Spread: 0.10 (200.00%)
Open: 0.125
High: 0.125
Low: 0.10
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licence and Product Supply Agreement with Tristel

23 Mar 2020 07:00

RNS Number : 1185H
Byotrol PLC
23 March 2020
 

 

 

 

 

Byotrol plc ("Byotrol" or the "Company")

Know-How Licence and Product Supply Agreement with Tristel plc

 

 

Byotrol is pleased to announce a new collaboration ("the Agreement") with fellow infection prevention and control specialists Tristel plc.

 

The Agreement relates to three specific technologies

 

1. A concentrated surface disinfectant initially targeted for use in hospitals, dispensed from Tristel's proprietary Cache system of innovative packaging solutions; and

2. A concentrated surface disinfectant with long-lasting (8 hour) anti-microbial efficacy also to be dispensed from Tristel's proprietary Cache system. This product is a concentrate version of ACTIZONE, a Solvay technology developed in conjunction with Byotrol; and

3. A unique surface disinfectant combining Tristel's proprietary sporicidal chemistry, with Byotrol's long-lasting anti-microbial technology, also based on the ACTIZONE technology platform. The combined product will speedily eliminate spores on application, and will then remain active against microbes for an 8-hour period after application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". 

The Agreement has a duration of 10 years and will be exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere. Under the terms of the Agreement, Tristel will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.

 

 

David Traynor, Chief Executive of Byotrol, said:

 

"We are really pleased to be working with Tristel in this way and are particularly pleased that our chemistries now work in combination, with genuinely unique new product claims at a key time in infection control. This agreement now brings our products to many more customers in healthcare and beyond, and in formats that we could not do on our own"

 

 

Enquiries:

 

Byotrol plc

David Traynor - Chief Executive Officer

Nic Hellyer - Chief Financial Officer 01925 742 000

 

finnCap

Geoff Nash/ Richard Chambers - Corporate Finance 020 7220 0500

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

 

Powerful, long-lasting and gentle, Byotrol's products can be used stand-alone or as ingredients within existing products, where Byotrol can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company develops technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRJTMMTMTMTTJM
Date   Source Headline
22nd Nov 20117:00 amRNSInterim Results
14th Nov 20114:40 pmRNSHolding(s) in Company
11th Nov 20119:46 amRNSHolding(s) in Company
9th Nov 20113:30 pmRNSHolding(s) in Company
7th Nov 201110:06 amRNSResult of EGM
21st Oct 20117:00 amRNSIssue of Equity to raise £2.46m
16th Sep 20117:00 amRNSChange of Adviser
21st Jul 20114:10 pmRNSResult of AGM
20th Jul 20117:00 amRNSMulti Country Contract with Rentokil
28th Jun 20112:39 pmRNSAnnual Financial Report and AGM notice
27th Jun 201112:14 pmRNSHolding(s) in Company
24th Jun 201110:53 amRNSHolding(s) in Company
21st Jun 20117:00 amRNSPreliminary Results
11th May 20117:00 amRNSDevelopment Contract with Fortune 150 Company
7th Apr 20115:20 pmRNSHolding(s) in Company
8th Feb 20117:00 amRNSAgreement with McBride on European Licence
9th Dec 20107:00 amRNSLicence Agreement with makers of Tommee Tippee
30th Nov 20102:39 pmRNSDirector/PDMR Shareholding
16th Nov 20107:00 amRNSInterim Results
23rd Sep 20105:18 pmRNSHolding(s) in Company
3rd Sep 201010:12 amRNSHolding(s) in Company
31st Aug 201012:01 pmRNSResult of General Meeting
19th Aug 201012:50 pmRNSGrant of Options
11th Aug 20107:00 amRNSIssue of Equity
29th Jul 20103:33 pmRNSResult of AGM
7th Jul 20107:00 amRNSJDA in UK & Ireland and Agreement Extension in US
6th Jul 20102:18 pmRNSAnnual Report and Notice of AGM
30th Jun 20107:00 amRNSContract to supply Odour Elimination goods in USA
25th Jun 20103:41 pmRNSDirector/PDMR Shareholding
22nd Jun 20104:02 pmRNSDirector/PDMR Shareholding
15th Jun 20107:00 amRNS2010 Preliminary Results
28th May 20107:00 amRNSResearch Grant, Patent Grant & Directorate Change
13th Apr 20101:38 pmRNSDirector/PDMR Shareholding
13th Apr 201010:16 amRNSDirector/PDMR Shareholding
30th Mar 20102:42 pmRNSDirector/PDMR Shareholding
25th Mar 201010:00 amRNSTrading update and results date
25th Mar 201010:00 amRNSDirectorate Change
26th Feb 201012:52 pmRNSTotal Voting Rights
4th Feb 20109:42 amRNSAcquisition of ByoFresh
22nd Dec 200911:40 amRNSHolding(s) in Company
22nd Dec 200911:40 amRNSHolding(s) in Company
21st Dec 20097:00 amRNSUS Patent and Option Agreement
1st Dec 20097:00 amRNSSociety of Food Hygiene & Technology Award
20th Nov 20097:00 amRNSDirector/PDMR Shareholding
17th Nov 20097:00 amRNSInterim Results
6th Oct 20097:00 amRNSTrading Statement
29th Sep 200911:59 amRNSHolding(s) in Company
17th Sep 20097:00 amRNSTrading Statement
11th Aug 20099:47 amRNSHolding(s) in Company
5th Aug 20097:00 amRNSUpdate on current business

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.